** Shares of healthcare company Allurion Technologies
** Company says initial data shows patients treated with its device along with low doses of Novo Nordisk's NOVOb.CO semaglutide resulted in average total body weight loss of 20.3% and lean body mass increase to 68.5%
** Company's device called Allurion Balloon occupies space in the stomach and is designed to promote satiety and reduce food consumption
** The balloon is non-surgical, swallowed and is designed to naturally empty and be eliminated about 4 months later - ALUR
** Company says all 52 patients remained adherent to the GLP-1 medication through eight months
** Additional data on the combination approach is being collected and is expected to be presented at upcoming medical meetings - company
** Stock had fallen 88.5% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。